Explore

Rapid Read Rapid Read
FDA Advisers Support Looser Rules for Compounding Unapproved Peptides, Raising Safety Concerns

FDA Advisers Support Looser Rules for Compounding Unapproved Peptides, Raising Safety Concerns

The Food and Drug Administration's (FDA) Pharmacy Compounding Advisory Committee recently voted in favor of allowing pharmacies to compound multiple unapproved peptides. This decision, made over a two-day meeting, has been met with enthusiasm from the wellness industry but has raised concerns within the medical community. Peptides, which are short strings of amino acids, are popular for their purported health benefits, including muscle recovery and longevity. Despite their popularity, the FDA had previously banned certain peptides due to potential safety risks, such as heart toxicity and infections. The committee's vote included approval for peptides like BPC-157 and TB-500, while others like emideltide were excluded. The FDA is not obligated to follow the committee's recommendations, but the decision highlights a growing demand for these compounds.
AP News AP News
FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers

FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers

Federal health advisers are recommending broader access to controversial chemicals called peptides
Rapid Read Rapid Read
FDA Panel Recommends Easing Access to Peptides Amid Safety Concerns

FDA Panel Recommends Easing Access to Peptides Amid Safety Concerns

An FDA advisory panel has narrowly recommended easing restrictions on several peptides, despite concerns from FDA scientists about their safety and efficacy. The panel voted 8-6 in favor of allowing pharmacies to compound peptides like BPC-157 and TB-500, which are popular among wellness influencers. The decision comes amid debates over the lack of human studies and potential risks associated with these substances. The FDA will review the panel's recommendations, which are not binding, before making a final decision. The outcome could impact the availability and regulation of peptides in the U.S.
Rapid Read Rapid Read
FDA Panel Recommends Easing Restrictions on Unapproved Peptides Despite Safety Concerns

FDA Panel Recommends Easing Restrictions on Unapproved Peptides Despite Safety Concerns

A panel of federal health advisers has recommended that the Food and Drug Administration (FDA) ease restrictions on several peptides, including BPC-157, TB-500, and KPV. These peptides are popular among wellness influencers and celebrities, despite warnings from FDA scientists about their safety and efficacy. The panel's decision, which is not binding, suggests adding these peptides to the FDA's list of substances considered safe for pharmacy compounding. This move could lead to increased marketing of these chemicals for wellness and cosmetic uses. The panel's vote was close, with an 8-6 outcome and one abstention, reflecting the panel's unusual composition, which included several members with ties to the peptide industry.
Rapid Read Rapid Read
FDA Advisory Committee Votes on Peptide BPC-157 Amid Safety Concerns

FDA Advisory Committee Votes on Peptide BPC-157 Amid Safety Concerns

The FDA's Pharmacy Compounding Advisory Committee (PCAC) has voted 8-6, with one abstention, to add the peptide BPC-157 to a drug compounding list, moving it closer to legal availability with a prescription. This decision is part of a broader review of seven peptides, which have gained popularity for purported health benefits like muscle building and metabolism improvement. Despite the vote, the decision is non-binding and requires FDA approval. The committee's consideration of an atypical regulatory pathway for these peptides has sparked debate, as there is limited human clinical trial data supporting their safety and effectiveness. Health Secretary Robert F. Kennedy Jr. has promoted peptide use, but the process has faced criticism over potential conflicts of interest among committee members.
Rapid Read Rapid Read
FDA Panel Supports Easier Access to Peptide Therapies Amid Safety Concerns

FDA Panel Supports Easier Access to Peptide Therapies Amid Safety Concerns

An advisory panel to the Food and Drug Administration (FDA) has recommended easing restrictions on peptide therapies, allowing specialized pharmacies in the U.S. to manufacture these compounds. Despite the FDA scientists' concerns about safety and lack of large-scale human trials, the panel voted in favor of making these experimental drugs more accessible. Peptides like BPC-157 and TB-500 are popular for their purported benefits in athletic performance and longevity. The decision comes amid a growing unregulated market where Americans are using unvetted substances sourced from overseas. Health Secretary Robert F. Kennedy Jr. has endorsed the move, emphasizing the need for a regulated market to ensure safety.
Rapid Read Rapid Read
FDA Panel Recommends Easing Restrictions on Peptide Drugs Amid Safety Concerns

FDA Panel Recommends Easing Restrictions on Peptide Drugs Amid Safety Concerns

A panel of federal health advisers has recommended that the Food and Drug Administration (FDA) ease restrictions on several peptides, which are popular among wellness influencers and celebrities. These peptides, including BPC-157, TB-500, and KPV, are currently restricted from being produced by pharmacies due to safety concerns. The panel's decision, which was made by a narrow vote of 8-6 with one abstention, suggests adding these peptides to the FDA's list of substances considered safe for pharmacy compounding. This recommendation comes despite warnings from FDA scientists about the lack of evidence supporting the safety and efficacy of these peptides. The panel included several members with ties to the peptide industry, which has raised concerns about the influence of market demand over scientific evidence.
Rapid Read Rapid Read
FDA to Review Peptide Regulations Amid Safety Concerns

FDA to Review Peptide Regulations Amid Safety Concerns

The U.S. Food and Drug Administration (FDA) is set to convene a panel of outside experts to discuss whether compounding pharmacies should be allowed to produce certain injectable peptides. These peptides, including TB-500, BPC-157, and MOTs-C, are popular in the wellness industry for their purported benefits in muscle growth, fat loss, and skin health. However, none of these compounds have undergone large-scale trials to establish their safety and efficacy, raising concerns among scientists and regulators. The FDA's Pharmacy Compounding Advisory Committee will review the evidence for these peptides over a two-day meeting. The discussion comes amid a growing demand for peptides, which has led to a gray market of unregulated suppliers.
Rapid Read Rapid Read
FDA Advisory Committee to Review Peptide Regulations in the U.S.

FDA Advisory Committee to Review Peptide Regulations in the U.S.

The U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee is set to meet to discuss the regulation of certain peptides, which are popular in wellness circles for their purported health benefits. The committee will consider whether compounding pharmacies should be allowed to dispense these peptides, which are not currently FDA-approved. The meeting is significant as it could determine the future accessibility of these substances, which are often used for muscle recovery, inflammation reduction, and overall health improvement. The committee's recommendations, while advisory, could influence the FDA's regulatory approach to these compounds.
AP News AP News
FDA reviews peptide injections favored by RFK Jr. and wellness influencers

FDA reviews peptide injections favored by RFK Jr. and wellness influencers

Federal health advisers are meeting to review a group of controversial chemicals called peptides
Rapid Read Rapid Read
FDA to Review Controversial Peptides Amid Rising Demand and Safety Concerns

FDA to Review Controversial Peptides Amid Rising Demand and Safety Concerns

The FDA is set to review the safety and efficacy of seven peptides, which have gained popularity for their purported wellness benefits, including sleep, muscle growth, and anti-aging. The Pharmacy Compounding Advisory Committee will meet to decide if these peptides can be produced by licensed compounding pharmacies. Despite their popularity, the FDA has raised concerns about the lack of substantial evidence supporting their safety and effectiveness. The review comes as peptides have been promoted by influencers and figures like Health Secretary Robert F. Kennedy Jr., who has advocated for their benefits. The FDA's decision will be influenced by the committee's recommendations, although these are not binding.
Rapid Read Rapid Read
FDA to Review Controversial Peptides Amid Rising Popularity and Safety Concerns

FDA to Review Controversial Peptides Amid Rising Popularity and Safety Concerns

The U.S. Food and Drug Administration (FDA) is set to review the safety and efficacy of seven peptides that have gained popularity for their purported health benefits, such as muscle growth and anti-aging. These compounds have been promoted by social media influencers and endorsed by Health Secretary Robert F. Kennedy Jr. Despite their popularity, the FDA has raised concerns about the lack of evidence supporting their safety and effectiveness. The review will determine whether these peptides can be made available through licensed pharmacies, potentially impacting their regulation and availability.